Lates News

On September 7th, Kangfang Biotech announced updated data from the first global multicenter Phase III clinical trial HARMONi of Ivosidenib (AK112) at the World Lung Cancer Congress. The study evaluated the efficacy and safety of Ivosidenib combined with chemotherapy in patients with disease progression after third-generation EGFR-TKI treatment. Results showed that the median follow-up time was 13.7 months, and the overall survival (OS) data significantly improved survival benefits in the North American population. Ivosidenib is the world's first PD-1/VEGF dual-antibody drug. In last year's domestic registration Phase III clinical trial (HARMONi-2) for first-line treatment of PD-L1-positive non-small cell lung cancer, Ivosidenib showed the potential to replace the PD-1 inhibitor Pembrolizumab (known as "Keytruda") with longer progression-free survival (PFS). Ivosidenib has gained fame as the hottest dual-antibody globally. (Daily Economic News)